Form 4: LeMaitre Vascular Director Receives Dividend Equivalents
Statement of Changes in Beneficial Ownership
Director Joseph P. Pellegrino Jr. acquired additional dividend equivalent rights related to existing equity awards.
Summary
- Director Joseph P. Pellegrino Jr. was granted a total of 17.1254 dividend equivalent rights on June 4, 2026.
- These rights accrued on various restricted stock unit (RSU) and performance share unit (PSU) awards granted between 2022 and 2025.
- Each dividend equivalent right represents the economic equivalent of one share of LeMaitre Vascular common stock.
- The acquisition of these rights does not represent a new open-market purchase but rather an adjustment to existing equity compensation holdings.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing with no impact on the company's financial health or strategic outlook.
Positives
- Reflects ongoing alignment of director interests with shareholders through equity-based compensation.
- Demonstrates the company's commitment to maintaining the economic value of director equity awards during dividend periods.
Negatives
- None identified; this is a routine administrative update regarding equity compensation.
Risks
- Value of these rights is tied to the future performance and market price of LeMaitre Vascular common stock.
Future Outlook
The rights will vest proportionately with the underlying RSU and PSU awards to which they are attached.
Industry Context
StockSavvy.ai notes that this filing is a standard regulatory disclosure for medical device companies, reflecting routine equity maintenance for board members rather than a change in strategic direction.
Comparison to Industry Standards
- Consistent with standard corporate governance practices for U.S. publicly traded companies regarding director compensation adjustments.
Stakeholder Impact
- Minimal impact on shareholders as this represents a minor adjustment to existing director compensation packages.
Next Steps
- Vesting of the underlying RSU and PSU awards in accordance with their original grant schedules.
Key Dates
| Date | Description |
|---|---|
| 2022-12-12 | Original grant date for 2022 RSU and PSU awards. |
| 2023-12-08 | Original grant date for 2023 RSU and PSU awards. |
| 2024-12-06 | Original grant date for 2024 RSU and PSU awards. |
| 2025-12-10 | Original grant date for 2025 RSU award. |
| 2026-06-04 | Transaction date for the accrual of dividend equivalent rights. |
| 2026-06-05 | Filing date of the Form 4. |
Keywords
LeMaitre Vascular, LMAT, Form 4, Director Compensation, Dividend Equivalent Rights, Insider Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.